Antidepressant Suicide Risk Eclipsed By Danger Of No Treatment – NIMH Chief
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA action to emphasize the risks of prescribing antidepressant drugs to children and adolescents would endanger minors with depression and run counter to the evidence emerging from a National Institute of Mental Health study, NIMH Director Insel says.
You may also be interested in...
Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says
FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.
Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield
VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.
NIH Alzheimer’s Initiative To Promote Neuroimaging, Identify Biomarkers
Program aimed at speeding Alzheimer’s drug development through neuroimaging and biomarkers is launched by the National Institute on Aging through a five-year, $60 mil. project. Large pharma companies are contributing funds to a multi-site study of 800 subjects.